GlassHouse Botanics Inc. Obtains Cultivation and Processing License from Health Canada
GlassHouse Botanics Inc. (GlassHouse), is thrilled to announce that it has received its Cultivation and Processing License from Health Canada. After months of intensive research, planning and construction this marks a significant milestone in their journey to becoming a global player in the medicinal cannabis industry.
With the completion of the first phase of construction, co-founders Dan Tauvette and Jeff Black, along with its management and cultivation team are extremely excited to begin cultivation of medicinal cannabis in their state-of-the-art, 43,000 square foot facility. Once fully built out, the GlassHouse facility will be comprised of 520,000 square feet of greenhouse and headhouse with a production capacity of over 50,000kg annually.
Significant progress is also being made globally as GlassHouse continues to focus on the largest medicinal cannabis market in the world – Europe. GlassHouse set up operations in Europe over six months ago to fulfill its long-term business plan of processing GMP grade medicinal cannabis for sale in the EU. This starts with being granted the appropriate licenses to carry on business in various countries. Once received, GlassHouse will commence construction on a EU-GMP certified facility to carryout R&D, extraction and processing of medicinal cannabis for sale in the European market.
GlassHouse Botanics Inc. is a privately-held Canadian corporation in the business of cultivation and processing of pharmaceutical-grade medicinal Cannabis flower and derivatives. The company’s facility is located in the Whitewater Region of Ontario, Canada, just over an hour West of Ottawa.
GlassHouse Botanics International Limited is a privately held company incorporated under the Malta Companies Act, 1995; located in Sliema Malta.